NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Editor’s Note November 29, 2011

OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: EpiCept Corporation [EPCT.PK]will present its Cancer product, Ceplene, approved in the European Union along with three other products, which stand as major clinical trial candidates: Amiket, Crobulin, and Azixa. S.E.A. Medical Systems, developing systems for intravenous drug delivery, will be presenting their technology at OneMedForum SF 2012. GlySure Limited has successfully demonstrated the ability to continuously monitor glucose levels for ICU patients' length of stay and is now rapidly preparing for regulatory trials in both the US and Europe.

To continue reading, please Login or Join